Opus Genetics Inc. Advances in Gene Therapy for Inherited Retinal Diseases

Opus Genetics Inc., a clinical-stage biotechnology company, has been actively engaging with the medical community by presenting its gene therapy programs for inherited retinal diseases at various medical conferences in May. The company’s research has shown promising results in treating retinitis pigmentosa, a group of inherited retinal dystrophies, through its innovative gene therapy approach.

The company’s advancements in gene therapy have been showcased at these conferences, highlighting the potential of its treatments for ophthalmic disorders. This focus on gene therapy positions Opus Genetics as a significant player in the biotechnology sector, particularly within the health care industry.

Despite experiencing fluctuations in its stock price, with a recent close price of $0.95 on May 13, 2025, below its 52-week average, the company’s research and development efforts continue to attract attention. The 52-week high was $2.18 on July 17, 2024, while the low was $0.65 on April 9, 2025. The market capitalization stands at $43,409,757 USD.

Opus Genetics operates in the United States, serving customers globally through its official website and the Nasdaq stock exchange. The company’s ongoing efforts in developing therapies for eye disorders underscore its commitment to advancing healthcare solutions in the biotechnology field.